Company
Akouos
Hearing Connects Us with One Another and the World Around Us
Also known as AKOUOS, INC.
- Business model
- B2B
- Legal name
- AKOUOS, INC.
Claim, correct or request removal
Record updated 28 September 2026
About
Akouos (AKUS) is a biotechnology company developing novel gene therapies for the treatment of monogenic forms of congenital deafness.
Funding snapshot
- Total raised
- $138MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- IPO2020-06-30
Funding rounds
- IPO
- 2020-06-30
- Round, 2020
- $105M2020-02-27, SEC form D sold, 33 investors
- Round, 2018
- $25.1M2018-07-17, SEC form D sold, 10 investors
- Round, 2017
- $7.6M2017-10-27, SEC form D sold, 8 investors
About the company
- Status notes
- As Akouos is now a wholly owned subsidiary of Eli Lilly and Company
Exit
- Acquisition
- 2022-10-18
Loading relationship preview